Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» SAGE Therapeutics
SAGE Therapeutics
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
FDA says no adcomm planned for Biogen, Sage's depression drug
FDA says no adcomm planned for Biogen, Sage's depression drug
Seeking Alpha
Biogen
SAGE Therapeutics
FDA
zuranolone
major depressive disorder
postpartum depression
Flag link:
Biogen, Sage Get FDA Priority Review of Zuranolone
Biogen, Sage Get FDA Priority Review of Zuranolone
Marketwatch
Biogen
SAGE Therapeutics
FDA
zuranolone
priority review
postpartum depression
major depressive disorder
Flag link:
JPM Day 2: Highlights
JPM Day 2: Highlights
BioSpace
JPMHC 2023
Relay Therapeutics
Sanofi
Scholar Rock
SAGE Therapeutics
Karuna Therapeutics
GSK
Flag link:
Biotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’
Biotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’
BioPharma Dive
SAGE Therapeutics
Jeff Jonas
Pharma CEOs
biotech
Abio-X
incubators
Flag link:
Sage, Biogen post fresh phase 3 depression data as FDA filing nears completion
Sage, Biogen post fresh phase 3 depression data as FDA filing nears completion
Fierce Biotech
SAGE Therapeutics
Biogen
zuranolone
postpartum depression
clinical trials
Flag link:
Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns
Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns
Endpoints
SAGE Therapeutics
Biogen
major depressive disorder
zuranolone
Flag link:
Chasing Sage, PureTech’s oral depression drug clears early bioavailability test
Chasing Sage, PureTech’s oral depression drug clears early bioavailability test
Fierce Pharma
PureTech Health
SAGE Therapeutics
allopregnanolone
clinical trials
clinical depression
Flag link:
Sage, Biogen drug meets goal in postpartum depression study
Sage, Biogen drug meets goal in postpartum depression study
BioPharma Dive
SAGE Therapeutics
Biogen
FDA
zuranolone
postpartum depression
Flag link:
Opportunities arise for once-spurned partners
Opportunities arise for once-spurned partners
EP Vantage
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
Flag link:
Sage, Biogen get rolling on FDA submission for depression med
Sage, Biogen get rolling on FDA submission for depression med
Fierce Biotech
SAGE Therapeutics
Biogen
zuranolone
FDA
major depressive disorder
Flag link:
Sage's phase 2 Alzheimer's drug shows signs of cognitive improvement—but there's a catch
Sage's phase 2 Alzheimer's drug shows signs of cognitive improvement—but there's a catch
Fierce Biotech
SAGE Therapeutics
SAGE-718
Alzheimer's disease
clinical trials
Flag link:
Significant readouts for small players
Significant readouts for small players
EP Vantage
clinical trials
SAGE Therapeutics
Biogen
Relmada
Athira Pharma
TauRx
Flag link:
Sage claims new data show depression drug works, but doubts remain
Sage claims new data show depression drug works, but doubts remain
Biopharma Dive
SAGE Therapeutics
Biogen
depression
clinical trials
zuranolone
Flag link:
Sage changes primary endpoint in key study months after analysts fret about depression drug's durability
Sage changes primary endpoint in key study months after analysts fret about depression drug's durability
Endpoints
SAGE Therapeutics
clinical trials
zuranolone
depression
endpoints
SSRIs
Flag link:
Biogen, Sage plot 2022 filing for zuranolone approval, furthering turnaround of depression drug
Biogen, Sage plot 2022 filing for zuranolone approval, furthering turnaround of depression drug
Fierce Biotech
Biogen
SAGE Therapeutics
zuranolone
FDA
clinical depression
Flag link:
Biogen and Sage Present Positive Data for Breakthrough Depression Therapy
Biogen and Sage Present Positive Data for Breakthrough Depression Therapy
BioSpace
Biogen
SAGE Therapeutics
major depressive disorder
postpartum depression
clinical trials
zuranolone
Flag link:
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Motley Fool
clinical trials
Novartis
Biogen
SAGE Therapeutics
uniQure
Pfizer
Roche
Flag link:
Sage Therapeutics Plunges After Depression Drug-Trial Results
Sage Therapeutics Plunges After Depression Drug-Trial Results
TheStreet.com
SAGE Therapeutics
clinical trials
depression
Biogen
zuranolone
Flag link:
Sage braces for make-or-break depression data
Sage braces for make-or-break depression data
BioPharma Dive
SAGE Therapeutics
earnings
major depressive disorder
Zulresso
Flag link:
Pages
1
2
3
4
5
next ›
last »